Format
Sort by
Items per page

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 177

1.

Safety and Efficacy of Current DAA Regimens in Kidney and Liver Transplant Recipients with Hepatitis C: Results from the HCV-TARGET Study.

Saxena V, Khungar V, Verna EC, Levitsky J, Brown RS, Hassan MA, Sulkowski MS, O'Leary JG, Koraishy F, Galati JS, Kuo AA, Vainorius M, Akushevich L, Nelson DR, Fried MW, Terrault N, Reddy KR.

Hepatology. 2017 May 15. doi: 10.1002/hep.29258. [Epub ahead of print]

PMID:
28504842
2.

Sofosbuvir-velpatasvir with ribavirin for 24 weeks in HCV patients previously treated with a direct-acting antiviral regimen.

Gane EJ, Shiffman ML, Etzkorn K, Morelli G, Stedman C, Davis MN, Hinestrosa F, Dvory-Sobol H, Huang KC, Osinusi A, McNally J, Brainard DM, McHutchison JG, Thompson AJ, Sulkowski MS; GS-US-342-1553 Investigators.

Hepatology. 2017 May 12. doi: 10.1002/hep.29256. [Epub ahead of print]

PMID:
28498551
3.

Barriers to Hepatitis C Virus (HCV) Treatment Initiation in Patients With Human Immunodeficiency Virus/HCV Coinfection: Lessons From the Interferon Era.

Wansom T, Falade-Nwulia O, Sutcliffe CG, Mehta SH, Moore RD, Thomas DL, Sulkowski MS.

Open Forum Infect Dis. 2017 Feb 11;4(1):ofx024. doi: 10.1093/ofid/ofx024. eCollection 2017 Winter.

4.

Reply to Ozaras et al.

Sulkowski MS, Brainard DM, Yang JC, Gane EJ.

Clin Infect Dis. 2017 May 15;64(10):1463. doi: 10.1093/cid/cix213. No abstract available.

PMID:
28444143
5.

Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis.

Kwo PY, Poordad F, Asatryan A, Wang S, Wyles DL, Hassanein T, Felizarta F, Sulkowski MS, Gane E, Maliakkal B, Overcash JS, Gordon SC, Muir AJ, Aguilar H, Agarwal K, Dore GJ, Lin CW, Liu R, Lovell SS, Ng TI, Kort J, Mensa FJ.

J Hepatol. 2017 Apr 13. pii: S0168-8278(17)30211-8. doi: 10.1016/j.jhep.2017.03.039. [Epub ahead of print]

PMID:
28412293
6.

Increased mortality among persons with chronic hepatitis C with moderate or severe liver disease: a cohort study.

Cepeda JA, Thomas DL, Astemborski J, Sulkowski MS, Kirk GD, Mehta SH.

Clin Infect Dis. 2017 Mar 10. doi: 10.1093/cid/cix207. [Epub ahead of print]

PMID:
28329108
7.

Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review.

Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, Fried MW, Segal JB, Sulkowski MS.

Ann Intern Med. 2017 May 2;166(9):637-648. doi: 10.7326/M16-2575. Epub 2017 Mar 21. Review.

8.

Challenges in treatment of hepatitis C among patients with hepatocellular carcinoma.

Saberi B, Dadabhai AS, Durand CM, Philosophe B, Cameron AM, Sulkowski MS, Gurakar A.

Hepatology. 2017 Feb 17. doi: 10.1002/hep.29126. [Epub ahead of print] No abstract available.

PMID:
28211073
9.

Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study.

Sulkowski MS, Fessel WJ, Lazzarin A, Berenguer J, Zakharova N, Cheinquer H, Côté P, Dieterich D, Gadano A, Matthews G, Molina JM, Moreno C, Pineda JA, Pulido F, Rivero A, Rockstroh J, Hernandez D, McPhee F, Eley T, Liu Z, Mendez P, Hughes E, Noviello S, Ackerman P.

Hepatol Int. 2017 Mar;11(2):188-198. doi: 10.1007/s12072-017-9788-z. Epub 2017 Feb 16.

PMID:
28210927
10.

Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment.

Poordad F, Felizarta F, Asatryan A, Sulkowski MS, Reindollar RW, Landis CS, Gordon SC, Flamm SL, Fried MW, Bernstein DE, Lin CW, Liu R, Lovell SS, Ng TI, Kort J, Mensa FJ.

Hepatology. 2017 Jan 27. doi: 10.1002/hep.29081. [Epub ahead of print]

PMID:
28128852
11.

Primary Care Providers Knowledge, Attitude and Practices Related to Hepatitis C Screening and Treatment in the Oral Direct Acting Antiviral Agents Era.

Falade-Nwulia O, McAdams-Mahmoud A, Irvin R, Niculescu A, Page KR, Mix M, Thomas DL, Sulkowski MS, Mehta SH.

J Community Med Health Educ. 2016 Oct;6(5). pii: 481. doi: 10.4172/2161-0711.1000481. Epub 2016 Oct 28.

12.

Short-duration treatment for chronic hepatitis C virus with daclatasvir, asunaprevir, beclabuvir and sofosbuvir (FOURward study).

Sulkowski MS, Flamm S, Kayali Z, Lawitz EJ, Kwo P, McPhee F, Torbeyns A, Hughes EA, Swenson ES, Yin PD, Linaberry M.

Liver Int. 2017 Jun;37(6):836-842. doi: 10.1111/liv.13335. Epub 2017 Feb 2.

PMID:
27943563
13.

Late Relapse Versus Hepatitis C Virus Reinfection in Patients With Sustained Virologic Response After Sofosbuvir-Based Therapies.

Sarrazin C, Isakov V, Svarovskaia ES, Hedskog C, Martin R, Chodavarapu K, Brainard DM, Miller MD, Mo H, Molina JM, Sulkowski MS.

Clin Infect Dis. 2017 Jan 1;64(1):44-52. Epub 2016 Oct 12.

PMID:
27737953
14.

Hepatitis C Virus Postexposure Prophylaxis in the Healthcare Worker: Why Direct-Acting Antivirals Don't Change a Thing.

Naggie S, Holland DP, Sulkowski MS, Thomas DL.

Clin Infect Dis. 2017 Jan 1;64(1):92-99. Epub 2016 Sep 28.

PMID:
27682067
15.

All-oral direct-acting antiviral therapy in HCV-advanced liver disease is effective in real-world practice: observations through HCV-TARGET database.

Reddy KR, Lim JK, Kuo A, Di Bisceglie AM, Galati JS, Morelli G, Everson GT, Kwo PY, Brown RS Jr, Sulkowski MS, Akuschevich L, Lok AS, Pockros PJ, Vainorius M, Terrault NA, Nelson DR, Fried MW, Manns MP; HCV-TARGET Study Group.

Aliment Pharmacol Ther. 2017 Jan;45(1):115-126. doi: 10.1111/apt.13823. Epub 2016 Oct 28.

PMID:
27790729
16.

Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response.

Terrault NA, Zeuzem S, Di Bisceglie AM, Lim JK, Pockros PJ, Frazier LM, Kuo A, Lok AS, Shiffman ML, Ben Ari Z, Akushevich L, Vainorius M, Sulkowski MS, Fried MW, Nelson DR; HCV-TARGET Study Group.

Gastroenterology. 2016 Dec;151(6):1131-1140.e5. doi: 10.1053/j.gastro.2016.08.004. Epub 2016 Aug 24.

PMID:
27565882
17.

Serum Fibrosis Markers for the Diagnosis of Liver Disease Among People With Chronic Hepatitis C in Chennai, India.

Cepeda JA, Solomon SS, Srikrishnan AK, Nandagopal P, Balakrishnan P, Kumar MS, Thomas DL, Sulkowski MS, Mehta SH.

Open Forum Infect Dis. 2016 Jul 23;3(3):ofw156. eCollection 2016 Sep.

18.

Cigarette Smoking Behaviors and Beliefs in Persons Living With Hepatitis C.

Shuter J, Litwin AH, Sulkowski MS, Feinstein A, Bursky-Tammam A, Maslak S, Weinberger AH, Esan H, Segal KS, Norton B.

Nicotine Tob Res. 2017 Jul 1;19(7):836-844. doi: 10.1093/ntr/ntw212.

PMID:
27613890
19.

No Evidence of Reactivation of Hepatitis B Virus Among Patients Treated With Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection.

Sulkowski MS, Chuang WL, Kao JH, Yang JC, Gao B, Brainard DM, Han KH, Gane E.

Clin Infect Dis. 2016 Nov 1;63(9):1202-1204. Epub 2016 Aug 2.

PMID:
27486112
20.

Ribavirin revisited in the era of direct-acting antiviral therapy for hepatitis C virus infection.

Feld JJ, Jacobson IM, Sulkowski MS, Poordad F, Tatsch F, Pawlotsky JM.

Liver Int. 2017 Jan;37(1):5-18. doi: 10.1111/liv.13212. Epub 2016 Sep 29. Review.

Supplemental Content

Loading ...
Support Center